medtechdive1d
Novocure wins FDA approval for electric field device in lung cancer
Alongside immunotherapy or chemo, the wearable device helped patients live longer in a trial, though the results are somewhat controversial.
JD Supra1d
Novacure’s Wearable Lung Cancer Treatment Device, Optune Lua, Receives FDA Approval
The FDA has granted approval for Novocure‘s wearable medical device, Optune Lua, designed to treat advanced non-small cell ...
MassDevice2d
Novocure wins FDA nod for lung cancer treatment wearable
Novocure announced on Tuesday that the FDA treated its Optune Lua wearable device for treating metastatic non-small cell lung ...
NovoCure scoops FDA approval on wearable for metastatic cancer treatment
Optune Lua received FDA approval based on data from the pivotal LUNAR trial which demonstrated significant median OS ...
BioWorld2d
Novocure’s tumor treating fields land FDA approval for lung cancer
Novocure GmbH secured U.S. FDA approval for Optune Lua, a wearable device that delivers alternating electric fields or tumor treating fields that kill cancer cells. Indicated for use with PD-1/PD-L1 ...
InnovationRx: This Startup’s Emotion-Sensing Glasses Could Be Used To Improve Mental Health
InnovationRx is your weekly digest of healthcare news. To get it in your inbox, subscribe here.
Investor's Business Daily on MSN3d
Novocure Withdraws Massive Gain On FDA Approval. Why It Could Struggle To Gain Traction.
Novocure stock advanced, but pulled back from massive gains after the FDA signed off on its cancer treatment device.
NovoCure’s Optune Lua Gains FDA Approval for NSCLC, Projecting Significant Sales Growth and Expansion
H.C. Wainwright analyst Emily Bodnar upgraded the rating on NovoCure (NVCR – Research Report) to a Buy today, setting a price target of ...
The American Journal of Managed Care3d
FDA Approves Optune Lua Device in NSCLC
Optune Lua creates tumor treating fields to disrupt cancer cell division, and it is used in conjunction with PD-1/PD-L1 ...
Targeted Oncology3d
FDA Oks Optune Lua for Use With PD-1/PD-L1 Inhibitors in Metastatic NSCLC
Following promising results from the phase 3 LUNAR trial, the FDA has approved Optune Lua for use with PD-1/PD-L1 inhibitors ...
FDA Approves NovoCure's Portable Device Producing Tumor-Treating Electric Fields For Previously Treated Lung Cancer Patients
Optune Lua for concurrent use with PD-1/PD-L1 inhibitors or docetaxel for adult patients with metastatic non-small cell lung ...
bovnews3d
Novocure’s (NVCR) Optune Lua Approval Sparks Market Surge
In a significant development for cancer treatment, Novocure (NASDAQ: NVCR) announced that the U.S. Food and Drug Administration (FDA) has approved its innovative device, Optune Lua®, for use in ...